Biogen Inc. $BIIB Stake Boosted by B. Riley Wealth Advisors Inc.

Key Points

• B. Riley Wealth Advisors increased its Biogen stake by 439.7% in the third quarter, bringing its holdings to 11,301 shares valued at approximately $2.55 million. Institutional investors own 87.93% of Biogen’s outstanding stock.
• Analyst sentiment is broadly positive: Biogen has a “Moderate Buy” consensus rating and an average price target of $236.04, with several brokerages recently upgrading the stock or raising their targets.
• Biogen reported quarterly earnings of $3.60 per share and revenue of $2.74 billion, exceeding analyst estimates; revenue increased 3.4% year over year, while the company issued full-year 2026 EPS guidance of $12.00–$13.00.

B. Riley Wealth Advisors Inc. grew its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 439.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,301 shares of the biotechnology company's stock after purchasing an additional 9,207 shares during the period. B. Riley Wealth Advisors Inc.'s holdings in Biogen were worth $2,553,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in Biogen during the second quarter worth about $3,453,878,000. Orbimed Advisors LLC purchased a new position in Biogen in the first quarter valued at about $11,293,000. Nippon Life Global Investors Americas Inc. purchased a new position in Biogen in the second quarter valued at about $29,648,000. Handelsbanken Fonder AB boosted its stake in Biogen by 12.7% in the second quarter. Handelsbanken Fonder AB now owns 93,236 shares of the biotechnology company's stock valued at $20,145,000 after acquiring an additional 10,510 shares during the last quarter. Finally, Tidal Investments LLC grew its position in shares of Biogen by 9.0% during the 2nd quarter. Tidal Investments LLC now owns 63,842 shares of the biotechnology company's stock valued at $13,794,000 after acquiring an additional 5,256 shares during the period. 87.93% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on BIIB. Canaccord Genuity Group raised their price target on shares of Biogen from $245.00 to $248.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. Truist Financial raised shares of Biogen from a "hold" rating to a "buy" rating and lifted their price target for the stock from $190.00 to $235.00 in a report on Monday, July 13th. Seaport Research Partners upgraded Biogen to an "outperform" rating in a research note on Monday. Wolfe Research upgraded Biogen from a "peer perform" rating to an "outperform" rating and set a $300.00 price objective on the stock in a research note on Thursday, August 13th. Finally, Oppenheimer reissued an "outperform" rating and set a $300.00 price objective on shares of Biogen in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Biogen has an average rating of "Moderate Buy" and a consensus price target of $236.04.

Biogen Price Performance

NASDAQ BIIB opened at $232.83 on Thursday. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. The company has a market cap of $34.40 billion, a PE ratio of 16.39, a price-to-earnings-growth ratio of 2.53 and a beta of 0.09. Biogen Inc. has a 52 week low of $138.00 and a 52 week high of $238.24. The firm's 50-day simple moving average is $218.89 and its two-hundred day simple moving average is $203.29.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The firm had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same quarter last year, the company earned $5.47 earnings per share. The company's revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Research analysts predict that Biogen Inc. will post 12.41 earnings per share for the current year.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen's products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich's ataxia.

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.